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Myelodysplastic syndromes (MDS) represent a hematologically diverse group of myeloid
neoplasms, however, one subtype characterized by an isolated deletion of chromosome
5q [del(5q)] is pathologically and clinically distinct. Patients with del(5q) MDS share biolog-
ical features that account for the profound hypoplastic anemia and unique sensitivity to
treatment with lenalidomide. Ineffective erythropoiesis in del(5q) MDS arises from allelic
deletion of the ribosomal processing S-14 (RPS14) gene, which leads to MDM2 seques-
tration with consequent p53 activation and erythroid cell death. Since its approval in 2005,
lenalidomide has changed the natural course of the disease. Patients who achieve transfu-
sion independence and/or a cytogenetic response with lenalidomide have a decreased risk
of progression to acute myeloid leukemia and an improved overall survival compared to non-
responders. Elucidation of the mechanisms of action of lenalidomide in del(5q) MDS has
advanced therapeutic strategies for this disease.The selective cytotoxicity of lenalidomide
in del(5q) clones derives from inhibition of a haplodeficient phosphatase whose catalytic
domain is encoded within the common deleted region on chromosome 5q, i.e., protein
phosphatase 2A (PP2Acα). PP2A is a highly conserved, dual specificity phosphatase that
plays an essential role in regulation of the G2/M checkpoint. Inhibition of PP2Acα results
in cell-cycle arrest and apoptosis in del(5q) cells. Targeted knockdown of PP2Acα using
siRNA is sufficient to sensitize non-del(5q) clones to lenalidomide. Through its inhibitory
effect on PP2A, lenalidomide stabilizes MDM2 to restore p53 degradation in erythroid
precursors, with subsequent arrest in G2/M. Unfortunately, the majority of patients with
del(5q) MDS develop resistance to lenalidomide over time associated with PP2Acα over-
expression. Targeted inhibition of PP2A with a more potent inhibitor has emerged as an
attractive therapeutic approach for patients with del(5q) MDS.
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INTRODUCTION
Myelodysplastic syndromes (MDS) represent both a clinical and
genetically heterogeneous group of clonal hematopoietic stem cell
disorders characterized by progressive cytopenias, dysplasia, and
risk of transformation into acute myeloid leukemia (AML). Cyto-
genetic characterization of MDS is a cornerstone of prognostic
assessment for overall survival and risk of AML evolution. Con-
ventional cytogenetic data are incorporated into both the Inter-
national Prognostic Scoring System (IPSS) and the revised-IPSS
(R-IPSS) (1, 2). However, chromosomal abnormalities are only
found in 52% of patients (3). Over recent years, there has been
considerable progress in the molecular characterization of MDS
with somatic mutations found in 80% or more of cases (4). The
molecular characterization of MDS adds further prognostic infor-
mation with mutations involvingTP53, EZH2, ETV6, RUNX1, and
ASXL1 associated with decreased overall survival and higher risk
of AML transformation (5, 6).
Myelodysplastic syndromes with isolated chromosome 5q dele-
tion [del(5q)] represents a distinct clinical and pathological entity
recognized in the World Health Organization (WHO) classifi-
cation. An interstitial deletion involving chromosome 5q is the
most common cytogenetic abnormality in MDS, accounting for
approximately 15% of MDS cases (3, 7). Of these, 50% have
isolated del(5q) while the remaining have either an additional
cytogenetic abnormality or a complex karyotype (3, 8). Del(5q)
MDS is characterized by hypoproliferative anemia with dysplas-
tic megakaryocytes and a rather indolent clinical course (9). Red
blood cell (RBC) transfusion dependence develops early in the
disease course and represents the principle driver of morbidity
and mortality. With the advent of exome sequencing, molecular
profiling has shown that 20% of patients with isolated del(5q)
MDS and 72% of patients with del(5q) accompanying a complex
karyotype harbor TP53 gene mutations (7). This genetic hetero-
geneity accounts for the prognostic heterogeneity in clinical course
and treatment outcome (8, 10). The following review is structured
chronologically as each major breakthrough in the field has fur-
ther defined the phenotype of del(5q) MDS and the critical role of
PP2A in the treatment of these patients. Together, these data high-
light novel therapeutic strategies in order to target the underlying
pathogenesis of this disease.
LENALIDOMIDE AND DEL(5q) MDS
Lenalidomide represents the first therapeutic agent in MDS, which
targets a cytogenetically defined disease subset. The initial evi-
dence of its clinical activity was based on a high clinical and
cytogenetic response rate in del(5q) MDS patients in the initial
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safety and efficacy study (11). Lenalidomide was approved by
the Food and Drug Administration (FDA) in 2005 for the treat-
ment of transfusion-dependent IPSS low or intermediate (int)-1
risk, del(5q) MDS. The approval was based on results of the
MDS-003 multicenter phase 2 trial in which 67% of patients
achieved transfusion independence (TI) with lenalidomide ther-
apy with a median TI duration of 2.2 years (12). In addition,
73% of patients had at least a partial cytogenetic response with
45% of patients achieving a complete response (CR). A recently
published long-term follow up of this study found that the
median overall survival was significantly increased in patients
who reached TI, 4.3 vs. 2 years in non-responders, and in cytoge-
netic responders, 4.9 vs. 3.1 years, respectively (13). Achievement
of TI or cytogenetic response also led to a decreased risk of
progression to AML.
DEL(5q) MDS PATHOBIOLOGY
The initial molecular understanding stemmed from genetic map-
ping experiments that identified two common deleted regions
(CDRs) in the 5q− syndrome (14, 15). The 5q− syndrome is
characterized by isolated del(5q), female predominance, refractory
macrocytic anemia accompanied by erythroid hypoplasia, normal
to increased platelet counts, normal to mildly decreased neu-
trophil counts, and hypolobated micromegakaryocytes (16, 17).
In patients with MDS or AML (excluding patients with 5q− syn-
drome), Horrigan et al. (15) identified a CDR at 5q31 (proximal
CDR) with a minimal deletion of 1 MB leading to presumed loss
of a tumor suppressor gene(s). In 5q− syndrome patients, deletion
mapping of the CDR identified a 1.5 MB interval at 5q32–33 (dis-
tal CDR) (14). The distal CDR contains 40 genes, 33 of which were
found to be expressed in CD34+ cells. Based on Knudson’s two-
hit hypothesis, extensive sequencing of 5q− syndrome patients
was performed to identify a possible second genetic event leading
to the malignant phenotype. Boultwood et al. (18) compared the
transcriptome of CD34+ cells from 5q− syndrome patients to
the transcriptome of CD34+ cells in healthy controls but did not
identify silenced genes in the remaining allele. A recent study uti-
lizing whole-exome sequencing on del(5q) patients at baseline and
at the time of leukemic transformation also found no mutations
in the residual alleles of the CDR (19).
Despite the absence of identifiable mutations to account for the
second-hit, expression of genes encoded within the CDR was con-
sistent with monoallelic expression (18). Of the candidate genes,
haploinsufficiency was evident in secreted protein acidic and rich
in cysteine (SPARC), a tumor suppressor gene, and ribosomal
processing S14 gene [RPS14 (component of 40S ribosomal sub-
unit)]. RPS14 haploinsufficiency was of particular interest given
that RPS19 mutations represent the most common genetic muta-
tion in patients with Diamond–Blackfan anemia (DBA), a con-
genital bone marrow failure syndrome with profound erythroid
hypoplasia (20). Furthermore, Gazda et al. (21) had shown that
haploinsufficiency of RPS19 was the underlying defect in a pro-
portion of patients with DBA (21). To determine the possible role
of RPS14 haploinsufficiency in the pathogenesis of del(5q) MDS,
Ebert and colleagues (22) designed lentiviral expressed short hair-
pin RNA (shRNA) as an RNA interference screen against each
of the 40 genes identified in the CDR (22). Utilizing this novel
methodology, only shRNA to RPS14 re-capitulated erythroid fea-
tures of the 5q− phenotype, producing erythroid maturation
arrest and impaired viability (22). RPS14 over-expression, in con-
trast, selectively rescued erythropoiesis in CD34+ cells of del(5q)
patients but not in non-del(5q) patients. Of importance, shRNA
to RPS14 down-regulated gene expression by 60%, compara-
ble to the haploinsufficient state of del(5q) patients. Further-
more, RPS14 haploinsufficiency was confirmed as the underly-
ing genetic abnormality underlying the hypoplastic anemia as
RPS14 gene sequencing in MDS patients showed absence of
point mutations, biallelic deletion, or epigenetic modification (i.e.,
methylation) (22).
The question of how RPS14 haploinsuffiency led to such a
dramatic deleterious effect on erythroid maturation without neg-
ative consequences on myeloid or megakaryocyte lineages has
recently been elucidated. Specifically, RPS14 haploinsufficiency
(via lentiviral shRNA) induced p53 accumulation in erythroid
precursors and subsequent cell-cycle arrest in a lineage specific
fashion (23). Impaired ribosome biogenesis as a result of RPS14
deficiency liberates free ribosomal proteins (RP) in the nucleo-
plasm, particularly RPL11, that bind to and sequester the human
homolog of the E3 ubiquitin ligase, mouse double minute 2 pro-
tein (MDM2), the major negative regulator of p53 (24). Degra-
dation of MDM2 drives p53 stabilization and activation (25).
Interference with the assembly of the 40S ribosomal subunit,
as occurs in RPS14 haploinsufficiency, induces up-regulation of
the RPL11 transcript (23, 24). Treatment of CD34+ cells with
Nutlin-3, a direct inhibitor of MDM2–p53 interaction (26), leads
to p53 accumulation and cell death primarily in the erythroid
lineage, providing a mechanistic rationale for the profound ane-
mia in del(5q) MDS (23). These data were reproduced in vivo
and occurred independent of ribosomal dysfunction, further
supporting heightened sensitivity to p53-mediated apoptosis in
erythroid precursors. Inhibition of p53 activity, via pifithrin-α,
abrogates this pathway, restoring normal erythropoiesis. Peller
and colleagues (27) had previously described p53 activation as
a critical molecular event involved in normal erythroid matu-
ration. The additional hit of ribosomal haploinsufficiency lead-
ing to p53 up-regulation in combination with a heightened
baseline activation of the p53 pathway in erythroid precursors
provide strong biological rationale for the erythroid phenotype
in del(5q) MDS.
In addition to significant macrocytic anemia, del(5q) patients
commonly have moderate neutropenia and thrombocytosis. The
mechanism underlying these hematological features has been
ascribed to deficiency of two microRNAs (miRNAs) encoded in
the distal CDR,miR-145 and miR-146a (28). Targeted knockdown
of these miRNAs in CD34+ cells leads to a pro-inflammatory
state with activation of tumor necrosis factor receptor-associated
factor-6 (TRAF6), inducing IL-6 and subsequent neutropenia,
thrombocytosis, and the dysplastic megakaryocytes character-
istic of del(5q) MDS (28, 29). Furthermore, down-regulation
of miR-145 induces Fli-1, a megakaryocyte and erythroid tran-
scription factor, accompanied by thrombocytosis (30). Com-
bined knockdown of RPS14 and miR-145 was sufficient to
re-capitulate the hematologic and pathologic phenotype of
del(5q) MDS (30).
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LENALIDOMIDE SELECTIVE CYTOTOXICITY IN DEL(5q) MDS
RESULTS FROM INHIBITION OF HAPLODEFICIENT
PHOSPHATASES
Just as allelic haplodeficiency of specific genes accounts for the
del(5q) MDS phenotype, gene dosage of two dual specificity phos-
phatases encoded within or adjacent to the proximal CDR at
5q31, CDC25C, and PP2Acα, underlies the selective suppression
of del(5q) clones by lenalidomide (31). Both of these phosphatases
play a pivotal co-regulatory role at the G2M checkpoint (32,
33). Phosphorylation of tyrosine (Tyr15) and threonine (Thr14)
residues within the ATP binding domain of cyclin-dependent
kinase-1 (CDK-1 or cdc2) inhibit CDK-1/Cyclin B complexes,
thereby blocking cell-cycle progression from G2 to M. Entry into
mitosis is mediated through PP2A dephosphorylation of Cdc25C
at the regulatory serine substrate (Ser216), leading to dissocia-
tion from the 14-3-3 binding protein and nuclear translocation
of the Cyclin B/cdc2 complex (34, 35). The above regulatory
pathway is depicted in Figure 1. Del(5q) cells in MDS or AML
patients were demonstrated to be haplodeficient for PP2Acα and
CDC25C. Lenalidomide-induced apoptosis in a concentration-
dependent fashion in del(5q) AML cells while demonstrating
no apoptotic effects in non-del(5q) patient cells or non-del(5q)
cell lines (31). Lenalidomide was shown to inhibit the activity of
Cdc25C and PP2Acα (as evidenced by retention of critical phos-
phate residues) by direct and indirect mechanisms, respectively. To
determine if inhibition of these phosphatases is directly responsi-
ble for the cytoselective toxicity of lenalidomide in del(5q) MDS,
knockdown of CDC25C and PP2cα using lentiviral shRNA was
performed in non-del(5q) cells to levels commensurate with hap-
lodeficiency. Down-regulation of CDC25C or PP2cα markedly
increased sensitivity to lenalidomide, and the pro-apoptotic effects
were additive with the dual gene knockdown. Of greater impor-
tance, these findings were replicated in non-del(5q) MDS bone
FIGURE 1 | CDC25C and PP2Acα regulatory role on cell cycle. Entry into
mitosis is mediated via PP2A dephosphorylation of Cdc25C, at the
regulatory serine substrate (Ser216), leading to 14-3-3 displacement and
nuclear translocation of the CyclinB/cdc2 complex. PP2A also regulates
phosphorylation of Cdc25A at Ser15. Phosphorylation of tyrosine (Tyr15) and
threonine (Thr14) residues within the ATP binding domain of
cyclin-dependent kinase-1 (CDK-1, or cdc2) inhibit CDK-1/Cyclin B
complexes and cell-cycle progression from G2 to M.
marrow mononuclear cells (MNC) with a threefold increase in
apoptosis and G2/M cell-cycle arrest.
PP2Acα: CRITICAL TARGET OF LENALIDOMIDE
Even though inhibition of the haplodeficient phosphatases
Cdc25C and PP2Acα can alone account for the selective cyto-
toxicity of lenalidomide in del(5q) cells, how this effect could be
reconciled in clones arrested in G1 by p53 activation warranted
further investigation (22, 31). Although cellular p53 expression
is up-regulated in bone marrow erythroid precursors of del(5q)
patients, lenalidomide stabilizes MDM2 to release cells from G1
arrest by modifying its phosphorylation as a result of PP2Acα
inhibition (36). Specifically, in Namalwa cells harboring a del(5q)
chromosomal abnormality and primary del(5q) MDS bone mar-
row MNC, lenalidomide induced MDM2 expression and conse-
quent p53 degradation. Over-expression of PP2Acα suppressed
MDM2 induction and restored p53 stabilization upon lenalido-
mide treatment, indicating that expression level of PP2Acα is a
key determinant of drug-induced p53 degradation.
The RPS14–MDM2 interaction arising from nucleolar stress in
del(5q) is disrupted by lenalidomide to foster transition to sub-
sequent G2/M arrest. PP2A is also recognized to modulate p53
through dephosphorylation of Thr55 and Ser46 residues, thereby
preventing proteasome targeted degradation (37, 38). Lenalido-
mide treatment promotes retention of the Thr55 and Ser46 phos-
phorylated residues with consequent down-regulation of cellular
p53 (36). In addition, lenalidomide specifically increased phos-
phorylation at critical regulatory sites at Ser166 and Ser186, inhibit-
ing auto-ubiquitination of MDM2 thereby leading to MDM2
nuclear translocation and p53 degradation. Phosphorylation of
Ser166 and Ser186 occurs through the kinase activity of Akt, which
is in turn regulated by PP2A (39, 40). Treatment with lenalido-
mide activated Akt as evidenced by increased phosphorylation at
Thr308 (36). PP2Acα association with MDM2 increased in a dose-
dependent manner after lenalidomide treatment while having no
direct effects on PP2Acα mRNA or protein expression. Together,
these data provide a biological rationale of lenalidomide mediated
p53 down-regulation in PP2Acα-haplodeficient del(5q) erythroid
precursors through PP2Acα inhibition and subsequent modula-
tion of MDM2 phosphorylation. To further validate PP2Acα as
the key regulator of MDM2 modulation by lenalidomide, lentivi-
ral PP2Acα shRNA were infected into non-del(5q) U937 cells
(36). Whereas knockdown of PP2Acα stabilized MDM2, CDC25c
down-regulation had no effect on MDM2 expression. Similarly,
decreased MDM2 expression using siRNA prevents lenalidomide-
mediated p53 degradation. The mechanism of lenalidomide’s dual
actions to suppress del(5q) clones while restoring and promoting
normal erythropoiesis is illustrated in Figure 2.
LENALIDOMIDE RESISTANCE IN DEL(5q) MDS IS
ASSOCIATED WITH PP2Acα OVER-EXPRESSION
PP2Acα and p53 expression in bone marrow trephine biopsies
were analyzed prior to therapy, at the time of TI/cytogenetic
response and at the time of treatment failure in a series of 22
del(5q) MDS patients treated with lenalidomide (36). Mean cel-
lular expression of p53 and PP2Acα significantly decreased with
treatment response. More importantly, at the time of treatment
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FIGURE 2 | Mechanism of action of lenalidomide in del(5q) MDS.
(A) Lenalidomide directly inhibits Cdc25C, resulting in G2/M arrest and
apoptosis in del(5q) cells. Lenalidomide also indirectly inhibits PP2A with
consequent Cdc25C inactivation. (B) Reduced expression of RPS14 results
in binding of free ribosomal proteins (RP) to MDM2, thereby triggering its
auto-ubiquitination and p53 accumulation. Lenalidomide inhibition of the
phosphatase PP2A results in hyperphosphorylation of MDM2 at Ser166 and
Ser186 and stabilization of MDM2, with consequent p53 degradation and
restored cell-cycle re-entry.
failure, PP2Acα was markedly up-regulated with restored expres-
sion of p53 in erythroid precursors, supporting our above in vitro
data that PP2Acα over expression promotes resistance to lenalido-
mide. PP2Acα up-regulation in lenalidomide-resistant patients
arose from a threefold increase in expression of the residual allele
with no evidence for gene amplification and/or mutations in
PP2Acα. Change in cellular PP2Acα expression emerged as a bio-
marker predictive for quality of response to lenalidomide, with the
magnitude of suppression at treatment response correlating with
duration of TI.
Primary resistance to lenalidomide has been linked to the pres-
ence of TP53 mutations in lower risk del(5q) MDS (41, 42). In
an analysis of the French and Spanish compassionate treatment
programs involving a total of 107 patients, cytogenetic response
to lenalidomide in del(5q) MDS ranged from 0 to 12% in patients
with mutated TP53 compared to 73% in patients with wild-type
(WT)TP53 (41–43). Similarly, all patients who experienced a cyto-
genetic response also achieved TI. Whereas 73% of patients with
WT-TP53 achieved TI, only 43% of patients with mutated TP53
achieved TI.These findings have important clinical implications as
recent studies indicate thatTP53 gene mutations are demonstrable
by deep sequencing in 18–20% of patients with isolated del(5q),
and in 70–100% in del(5q) in combination with aberrations of
chromosome 7 and/or 17 (7, 43). Moreover, ability to reach TI
and cytogenetic response are directly related to OS and risk of
AML transformation in patients treated with lenalidomide (13).
Molecular stratification of MDS patients by TP53 mutation status
has shown decreased survival in patients harboring aTP53 mutant
clone (5), indicating that this is a critical prognostic marker that
is also predictive for potential benefit from lenalidomide treat-
ment. To this end, Saft and colleagues (44) recently reported a
retrospective study of the prognostic significance of cellular p53
expression detected by immunohistochemical staining and TP53
gene mutation in a series of IPSS low or int-1 risk del(5q) MDS
patients treated with lenalidomide in the MDS-004 trial (44, 45).
Strong cellular p53 expression by IHC in ≥1% of bone marrow
precursors strongly correlated with decreased cytogenetic response
(P = 0.009), higher risk of leukemic transformation (P = 0.00006)
and shorter overall survival (P = 0.0175) (44). Strong p53 positiv-
ity directly correlated with TP53 mutation whereas moderate pos-
itivity correlated with WT-TP53. Presence of strong p53 staining
was the most important prognostic co-variate for risk of leukemic
transformation, which accounts in part for the apparent hetero-
geneity of risk in isolated del(5q) patients. This was exemplified
by the MDS-004 trial where 3-year OS and AML transformation
rates were 56 and 25%, respectively, which correlates with high
percentage of strongly p53+ patients in this trial (35%) (44, 45).
Furthermore, sequential whole-exome sequencing of two del(5q)
patients at baseline and at AML transformation identified TP53
mutations in both patients at the time of leukemic transformation
[but not in two non-del(5q) patients], suggesting thatTP53 muta-
tion is the critical event in progression of del(5q) MDS (19). The
precise reason for the disproportionate prevalence of TP53 gene
mutations in del(5q) MDS is unknown, but one could speculate
that mutant clones may be selected for under the pressure of con-
stitutive activation of this pathway in this particular cytogenetic
MDS subset, analogous to other cancers in which such mutations
emerge in the presence of ongoing cellular stress or DNA-damage
response activation (46). Targeting the RPS14–MDM2–p53 path-
way by PP2A inhibition or alternative therapeutic strategies could
prove to alter the natural course of the disease by preventing clonal
evolution and transformation to leukemia. As sustained suppres-
sion of p53 would lead to genomic instability (46), careful clinical
investigation needs to be performed to balance clinical benefit with
potential risk.
NOVEL THERAPEUTIC STRATEGIES FOR DEL(5q) MDS
As described above, PP2Acα is a key target of lenalidomide leading
to modulation of the RP–MDM2–P53 pathway, clonal suppres-
sion, and restoration of normal erythropoiesis. Unfortunately,
approximately 50% of patients develop resistance to lenalidomide
after 2–3 years of treatment and there are currently no alternative
karyotype selective therapeutic agents (13, 47). Given that PP2Acα
over-expression underlies lenalidomide resistance, novel strategies
targeting this pathway are of pivotal importance (Figure 3). This
is reinforced by our findings that duration of TI to lenalidomide
was directly related to the magnitude of PP2Acα suppression (36).
Specifically, median duration of TI was not reached in patients
with PP2Acα suppression from baseline (1507+ days) versus
679 days in patients without (P = 0.006, log rank).
One potential strategy is development of more potent and
specific inhibitors of PP2A. Okadaic acid, a derivative of shell-
fish toxin, inhibits both PP2A and PP1 (48). LB-100 and LB-102
are synthetic derivatives of cantharadin, a demethylated homolog
of cantharadin (extract of beetle juice), which is an inhibitor of
PP2A with relative specificity in vitro and in vivo and acceptable
toxicity (49–52). LB-102 was shown to increase Akt phosphory-
lation and decrease p53 expression in malignant glioma cells and
xenografts (50). LB-100/LB-102 blocked cell-cycle arrest and led
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FIGURE 3 | Pathogenesis of the del(5q) MDS hematologic phenotype
and novel therapeutic strategies to rescue erythropoiesis. Allelic
deletion of the genes encoded in the del(5q) CDR disrupts ribosomal
integrity via haploinsufficiency of RPS14 leading to RP, e.g., RPL11,
sequestration of MDM2 and consequent p53 activation. PP2A is a negative
regulatory phosphatase of MDM2 whose inhibition results in
hyperphosphorylation at phosphate residues that protect it from
ubiquitination. Lenalidomide abrogates the anemia in del(5q) MDS through
PP2A inhibition. CP2-221 is a deuterium-modified analog of S-lenalidomide
enantiomer with greater potency than the parent compound. LB-100 is a
novel direct PP2A inhibitor that has entered clinical testing. Lastly, p53
modulation via dexamethasone and/or cenersen (p53 antisense) are exciting
potential clinical strategies that are currently under clinical investigation.
to chemotherapy sensitization to temozolomide and doxorubicin
(50, 52). LB-100 was also shown to induce tumor differentiation
and/or cell death in glioblastoma multiforme (53). LB-100 has
now entered a phase 1 clinical trial as a chemotherapy sensitizer
in solid tumors (NCT01837667) (54). A phase 1 clinical trial of
LB-100 is planned in lower risk MDS patients with symptomatic
anemia, including del(5q) MDS patients who are resistant and/or
intolerant to lenalidomide. This would be a first in class novel
inhibitor as there are currently no FDA approved phosphatase
inhibitors. Another potential strategy to enhance PP2Acα inhibi-
tion would be using the lenalidomide analog, CPT-221. CP2-221 is
a deuterium-modified analog of S-lenalidomide (lenalidomide is
a racemic mixture of S- and R-enantiomers). In vitro studies have
shown that CPT-221 is threefold to fivefold more potent than the
lenalidomide racemic mixture (55). Investigation of CPT-221 in
the treatment of MDS patients has not yet been initiated.
Given that p53 accumulation in erythroid precursors is respon-
sible for the hypoplastic anemia in del(5q) MDS, targeting p53
directly could restore terminal differentiation and effective ery-
thropoiesis in the del(5q) clone. Cenersen, a clinically active 20-
mer antisense phosphorothioate oligonucleotide complementary
to exon 10, down-regulates both WT and mutant TP53 expres-
sion in vitro and in vivo when administered in combination with
chemotherapy in patients with hematologic malignancies (56–58).
Cenersen treatment of RPS14 deficient erythroblasts, to simulate
the haplodeficient state in del(5q) cells, decreased cellular expres-
sion of TP53, leading to improved cell survival (59). Treatment of
bone marrow CD34+ cells from lenalidomide resistant, del(5q)
MDS with cenersen dramatically increased erythroid colony for-
mation with less improvement in non-del(5q) or normal controls.
Of interest, cenersen had no suppressive effect on the del(5q) clone,
thereby supporting the notion that p53 suppression restored ery-
thropoietic potential within the malignant clone (Figure 2). A
phase 1 clinical trial testing cenersen in del(5q) MDS patients resis-
tant and/or intolerant to lenalidomide therapy is now underway.
As proof of this biological principle, Caceres et al. (59) tested the
addition of dexamethasone, a glucocorticoid-receptor-dependent
p53 antagonist, to lenalidomide treatment in del(5q) MDS patients
who acquired resistance to lenalidomide. In this pilot study, 20 mg
of weekly dexamethasone down-regulated p53 expression in ery-
throid progenitors and consequently restored TI in five of eight
patients. The potential to achieve targeted suppression of WT and
mutant TP53 with cenersen is exciting, given the decreased effi-
cacy of lenalidomide in patients with a TP53 mutation (41–43).
Of particular interest, Woll and colleagues (60) recently discov-
ered that acquired driver mutations in the malignant stem cells of
del(5q) MDS patients, especially TP53, emerge prior to leukemic
transformation. This builds on prior work, which also showed
that chromosome 5q deletion is the initial inciting event and is
present in both the progenitor and malignant stem cells of these
patients (60, 61). These stem cells that harbor del(5q) are intrin-
sically resistant to lenalidomide secondary to their quiescent state
(61). Acquisition of TP53 mutations could foster propagation of
myeloid progenitor cells leading to hematologic relapse and dis-
ease progression in these patients. Targeting of WT and mutated
TP53 could prove to be a promising therapeutic strategy in possibly
achieving and/or prolonging remissions in del(5q) MDS patients
treated with lenalidomide.
CONCLUSION
Myelodysplastic syndromes with isolated del(5q) represents a dis-
tinct disease subtype distinguished by clinical presentation and
unique sensitivity to lenalidomide. These pathognomonic fea-
tures are directly linked to haplodeficiency of critical targets in
the CDR on chromosome 5q. Severe anemia constitutes the major
morbidity/mortality for del(5q) MDS patients and arises from
RPS14 haplodeficiency leading to MDM2 sequestration, p53 sta-
bilization, and erythroid cell death. Lenalidomide inhibits this
pathway through its inhibitory effect on PP2A, rescuing erythro-
poiesis. Lenalidomide’s selective cytotoxity to del(5q) cells arises
from inhibition of two haplodeficient phosphatases, PP2Acα and
Cdc25C. Clonal suppression of del(5q) is of pivotal importance
in preventing leukemic transformation and death. However, resis-
tance to treatment emerges over time and future studies targeting
PP2A and/or the RP–MDM2–p53 axis should be a priority to
improve outcomes in this patient population.
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